{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T22:39:26Z","timestamp":1788043166838,"version":"build-2784847793"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"11-12","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GRK 2254 (HEIST)"],"award-info":[{"award-number":["GRK 2254 (HEIST)"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum Ulm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Cluster of differentiation 44 variant 6 (CD44v6) has been described in various types of cancer, including liver cancer. Despite significant advancements in cancer therapy, there is still an urgent medical need for new therapeutic strategies for the treatment of liver tumours that are efficacious but well tolerated. One promising approach involves the use of small molecules, such as peptides, which intervene in central signalling pathways to prevent the migration of cancer cells and their invasion into other organs without affecting other cell types. We analysed the expression of CD44v6 in human cirrhotic livers, liver tumour tissues and organoids as well as in preclinical models of chronic liver disease and subsequent liver tumour formation. We overexpressed CD44v6 in CD44v6-negative cell lines to assess its impact on the functionality of cancer cells. Furthermore, we used AMC303, a peptide inhibitor that specifically binds to CD44v6, to investigate the consequences of CD44v6 inhibition in liver cancer and its impact on combination therapies. We demonstrated that CD44v6 is expressed in chronic liver conditions, and is overexpressed in liver cancer, where it serves as a cancer stem cell marker. We also established that CD44v6 influences migration and stemness in liver cancer, and its overexpression triggers an altered gene expression pattern including increased EMT and stemness signatures. Notably, we were able to increase the efficacy of TKI\/chemotherapeutics by inhibiting CD44v6. In summary, inhibition of CD44v6 renders liver carcinomas more susceptible to therapeutic intervention, thereby representing a promising target for cotreatment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key messages<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>CD44v6 is expressed in chronic liver disease and is overexpressed in liver cancer.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>CD44v6 has been demonstrated to exert a significant influence on the processes of migration and stemness in liver cancer.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Overexpression of CD44v6 triggers an altered gene expression pattern, characterized by an increase in EMT and stemness signatures.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Inhibition of CD44v6 increases the efficacy of TKI\/chemotherapeutics in cell lines and organoids generated from liver carcinoma.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>CD44v6 inhibition renders liver carcinomas more susceptible to therapeutic intervention, thereby representing a promising target for cotreatment strategies.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00109-025-02601-5","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:33:16Z","timestamp":1761870796000},"page":"1583-1598","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Peptide-based inhibition of CD44v6 renders liver carcinomas more susceptible to therapeutic intervention"],"prefix":"10.1007","volume":"103","author":[{"given":"Akshaya","family":"Srikanth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjitha Vishnu Anand","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh","family":"Tharehalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F. E.","family":"Barth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Dembowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Seufferlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhold","family":"Schirmbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0221-6959","authenticated-orcid":false,"given":"Andr\u00e9","family":"Lechel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"2601_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3023","author":"M Z\u00f6ller","year":"2011","unstructured":"Z\u00f6ller M (2011) CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer. https:\/\/doi.org\/10.1038\/nrc3023","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2601_CR2","first-page":"8","volume":"67","author":"BF Flanagan","year":"1989","unstructured":"Flanagan BF, Dalchau R, Allen AK, Daar AS, Fabre JW (1989) Chemical composition and tissue distribution of the human CDw44 glycoprotein. Immunology 67(2):8","journal-title":"Immunology"},{"key":"2601_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(00)80192-0","volume":"32","author":"K Endo","year":"2000","unstructured":"Endo K, Terada T (2000) Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J Hepatol 32:6","journal-title":"J Hepatol"},{"issue":"6","key":"2601_CR4","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2018.05.003","volume":"33","author":"D Dhar","year":"2018","unstructured":"Dhar D, Antonucci L, Nakagawa H, Kim JY, Glitzner E, Caruso S, Shalapour S, Yang L, Valasek MA, Lee S, Minnich K, Seki E, Tuckermann J, Sibilia M, Zucman-Rossi J, Karin M (2018) Liver cancer initiation requires p53 inhibition by CD44-enhanced growth factor signaling. Cancer Cell 33(6):1061-1077.e6","journal-title":"Cancer Cell"},{"issue":"1","key":"2601_CR5","doi-asserted-by":"publisher","DOI":"10.4174\/astr.2015.89.1.9","volume":"89","author":"R Kim","year":"2015","unstructured":"Kim R, Kim SB, Cho E-H, Park SH, Park SB, Hong SK, Chae G (2015) CD44 expression in patients with combined hepatocellular cholangiocarcinoma. Ann Surg Treat Res 89(1):9","journal-title":"Ann Surg Treat Res"},{"issue":"6","key":"2601_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-019-02539-3","volume":"474","author":"AS Garcia","year":"2019","unstructured":"Garcia AS, Assao A, Carvalho AL, Soares FA, Kowalski LP, Oliveira DT (2019) The stem cell markers expression CD44v6 and podoplanin in lip cancer: clinical significance. Virchows Arch 474(6):9","journal-title":"Virchows Arch"},{"issue":"1","key":"2601_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1042\/BSR20100018","volume":"31","author":"M Gaviraghi","year":"2011","unstructured":"Gaviraghi M, Tunici P, Valensin S, Rossi M, Giordano C, Magnoni L, Dandrea M, Montagna L, Ritelli R, Scarpa A, Bakker A (2011) Pancreatic cancer spheres are more than just aggregates of stem marker-positive cells. Biosci Rep 31(1):45\u201355","journal-title":"Biosci Rep"},{"issue":"8","key":"2601_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2009.54","volume":"89","author":"EL Snyder","year":"2009","unstructured":"Snyder EL, Bailey D, Shipitsin M, Polyak K, Loda M (2009) Identification of CD44v6+\/CD24\u2212 breast carcinoma cells in primary human tumors by quantum dot-conjugated antibodies. Lab Invest 89(8):9","journal-title":"Lab Invest"},{"key":"2601_CR9","doi-asserted-by":"crossref","unstructured":"Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, Apuzzo T, Sperduti I, Volpe S, Cocorullo G, Gulotta G, Dieli, Ruggero F, and Stassi G (2014)\u00a0CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell\u00a014(3):342\u2013356.","DOI":"10.1016\/j.stem.2014.01.009"},{"key":"2601_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1508-1","author":"X Wang","year":"2019","unstructured":"Wang X, Wang R, Bai S, Xiong S, Li Y, Liu M, Zhao Z, Wang Y, Zhao Y, Chen W, Billiar TR, Cheng B (2019) Musashi2 contributes to the maintenance of CD44v6+ liver cancer stem cells via Notch1 signaling pathway. J Exp Clin Cancer Res. https:\/\/doi.org\/10.1186\/s13046-019-1508-1","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"2601_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.02.024","volume":"46","author":"V Orian-Rousseau","year":"2010","unstructured":"Orian-Rousseau V (2010) CD44, a therapeutic target for metastasising tumours. Eur J Cancer 46(7):6","journal-title":"Eur J Cancer"},{"key":"2601_CR12","doi-asserted-by":"crossref","unstructured":"Castella EM, Ariza A, Ojanguren I, Mate JL, Roca X, Fernandez-Vasalo A, and Navas-Palacios JJ (1996)\u00a0Differential expression of CD44v6 in adenocarcinoma of the pancreas: an immunohistochemical study. Virchows Archiv\u00a0429\u2013429(4\u20135).","DOI":"10.1007\/BF00198333"},{"issue":"3\u20134","key":"2601_CR13","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1159\/000452570","volume":"40","author":"M Fang","year":"2016","unstructured":"Fang M, Wu J, Lai X, Ai H, Tao Y, Zhu B, Huang L (2016) CD44 and CD44v6 are correlated with gastric cancer progression and poor patient prognosis: evidence from 42 studies. Cell Physiol Biochem 40(3\u20134):567\u2013578","journal-title":"Cell Physiol Biochem"},{"issue":"6","key":"2601_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2015.03.001","volume":"39","author":"Y Fu","year":"2015","unstructured":"Fu Y, Geng Y, Yang N, Zhu N, Wang C-Z, Su X-C, Zhang H-B (2015) CD44v6 expression is associated with a poor prognosis in Chinese hepatocellular carcinoma patients: a meta-analysis. Clin Res Hepatol Gastroenterol 39(6):3","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"4","key":"2601_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1447-0756.2006.00422.x","volume":"32","author":"SC Hong","year":"2006","unstructured":"Hong SC, Song JY, Lee JK, Lee NW, Kim SH, Yeom BW, Lee KW (2006) Significance of CD44v6 expression in gynecologic malignancies. J Obstet Gynaecol Res 32(4):7","journal-title":"J Obstet Gynaecol Res"},{"key":"2601_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001238","author":"B Hu","year":"2015","unstructured":"Hu B, Luo W, Hu R-T, Zhou Y, Qin S-Y, Jiang H-X (2015) Meta-analysis of prognostic and clinical significance of CD44v6 in esophageal cancer. Medicine (Baltimore). https:\/\/doi.org\/10.1097\/MD.0000000000001238","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"2601_CR17","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/pros.22775","volume":"74","author":"J Ni","year":"2014","unstructured":"Ni J, Cozzi PJ, Hao JL, Beretov J, Chang L, Duan W, Shigdar S, Delprado WJ, Graham PH, Bucci J, Kearsley JH, Li Y (2014) CD44 variant 6 is associated with prostate cancer metastasis and chemo-\/radioresistance. Prostate 74(6):602\u2013617","journal-title":"Prostate"},{"key":"2601_CR18","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.2147\/OTT.S156101","volume":"11","author":"G-L Qiao","year":"2018","unstructured":"Qiao G-L, Song L-N, Deng Z-F, Chen Y, Ma L-J (2018) Prognostic value of CD44v6 expression in breast cancer: a meta-analysis. OncoTargets Ther 11:5451\u20135457","journal-title":"OncoTargets Ther"},{"issue":"3","key":"2601_CR19","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.3390\/ijms16034372","volume":"16","author":"\u00c1 Ruibal","year":"2015","unstructured":"Ruibal \u00c1, Aguiar P, Del R\u00edo M, Nu\u00f1ez M, Pubul V, Herranz M (2015) Cell membrane CD44v6 levels in squamous cell carcinoma of the lung: association with high cellular proliferation and high concentrations of EGFR and CD44v5. Int J Mol Sci 16(3):4372\u20134378","journal-title":"Int J Mol Sci"},{"key":"2601_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13018-015-0328-z","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Ding C, Wang J, Sun G, Cao Y, Xu L, Zhou L, Chen X (2015) Prognostic significance of CD44V6 expression in osteosarcoma: a meta-analysis. J Orthop Surg Res. https:\/\/doi.org\/10.1186\/s13018-015-0328-z","journal-title":"J Orthop Surg Res"},{"issue":"3","key":"2601_CR21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1177\/039463201402700304","volume":"27","author":"M Athanassiou-Papaefthymiou","year":"2014","unstructured":"Athanassiou-Papaefthymiou M, Shkeir O, Kim D, Divi V, Matossian M, Owen JH, Czerwinski MJ, Papagerakis P, McHugh J, Bradford CR, Carey TE, Wolf GT, Prince ME, Papagerakis S (2014) Evaluation of CD44 variant expression in oral, head and neck squamous cell carcinomas using a triple approach and its clinical significance. Int J Immunopathol Pharmacol 27(3):337\u2013349","journal-title":"Int J Immunopathol Pharmacol"},{"key":"2601_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-1265-7","author":"L Ma","year":"2019","unstructured":"Ma L, Dong L, Chang P (2019) CD44v6 engages in colorectal cancer progression. Cell Death Dis. https:\/\/doi.org\/10.1038\/s41419-018-1265-7","journal-title":"Cell Death Dis"},{"issue":"2","key":"2601_CR23","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1053\/j.gastro.2015.10.020","volume":"150","author":"A Matzke-Ogi","year":"2016","unstructured":"Matzke-Ogi A, Jannasch K, Shatirishvili M, Fuchs B, Chiblak S, Morton J, Tawk B, Lindner T, Sansom O, Alves F, Warth A, Schwager C, Mier W, Kleeff J, Ponta H, Abdollahi A, Orian-Rousseau V (2016) Inhibition of tumor growth and metastasis in pancreatic cancer models by interference with CD44v6 signaling. Gastroenterology 150(2):513-525.e10","journal-title":"Gastroenterology"},{"issue":"21","key":"2601_CR24","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.21037\/atm-19-4781","volume":"8","author":"D Zhang","year":"2020","unstructured":"Zhang D, Huang J, Li W, Zhang Z, Zhu M, Feng Y, Zhao Y, Li Y, Lu S, He S (2020) Screening and identification of a CD44v6 specific peptide using improved phage display for gastric cancer targeting. Ann Transl Med 8(21):1442\u20131442","journal-title":"Ann Transl Med"},{"key":"2601_CR25","doi-asserted-by":"crossref","unstructured":"Al-Rawi V, Laeufer T, Glocker K, Heneka Y, and Matzke-Ogi A (2017)\u00a0Allosteric inhibition of the receptor tyrosine kinases c-MET, RON and VEGFR-2 via the co-receptor CD44v6 by the novel compound AMC303 in AACR. 2017. Washington D. C: Cancer Research.","DOI":"10.1158\/1538-7445.AM2017-4911"},{"key":"2601_CR26","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0207","author":"A Matzke","year":"2005","unstructured":"Matzke A, Herrlich P, Ponta H, Orian-Rousseau V (2005) A five-amino-acid peptide blocks Met- and Ron-dependent cell migration. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-0207","journal-title":"Cancer Res"},{"key":"2601_CR27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-219204","author":"M Tremmel","year":"2009","unstructured":"Tremmel M, Matzke A, Albrecht I, Laib AM, Olaku V, Ballmer-Hofer K, Christofori G, Heroult M, Augustin HG, Ponta H, Orian-Rousseau V (2009) A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis. Blood. https:\/\/doi.org\/10.1182\/blood-2009-04-219204","journal-title":"Blood"},{"issue":"3","key":"2601_CR28","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3892\/ijo.2014.2529","volume":"45","author":"V Castillo","year":"2014","unstructured":"Castillo V, Valenzuela R, Huidobro C, Contreras HR, Castellon EA (2014) Functional characteristics of cancer stem cells and their role in drug resistance of prostate cancer. Int J Oncol 45(3):985\u2013994","journal-title":"Int J Oncol"},{"key":"2601_CR29","doi-asserted-by":"crossref","unstructured":"Xu H, Tian Y, Yuan X, Wu H, Liu Q, Pestell RG, Wu K\u00a0(2015) The role of CD44 in epithelial-mesenchymal transition and cancer development. Onco Targets Ther 8:3783\u20133792","DOI":"10.2147\/OTT.S95470"},{"issue":"9","key":"2601_CR30","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1002\/cam4.4497","volume":"11","author":"P Dubey","year":"2022","unstructured":"Dubey P, Gupta R, Mishra A, Kumar V, Bhadauria S, Bhatt MLB (2022) Evaluation of correlation between CD44, radiotherapy response, and survival rate in patients with advanced stage of head and neck squamous cell carcinoma (HNSCC). Cancer Med 11(9):1937\u20131947","journal-title":"Cancer Med"},{"key":"2601_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174147","author":"Z Yaghobi","year":"2021","unstructured":"Yaghobi Z, Movassaghpour A, Talebi M, Shadbad MA, Hajiasgharzadeh K, Pourvahdani S, Baradaran B (2021) The role of CD44 in cancer chemoresistance: a concise review. Eur J Pharmacol. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174147","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"2601_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29097","volume":"136","author":"J Fernando","year":"2015","unstructured":"Fernando J, Malfettone A, Cepeda EB, Vilarrasa-Blasi R, Bertran E, Raimondi G, Fabra \u00c0, Alvarez-Barrientos A, Fern\u00e1ndez-Salguero P, Fern\u00e1ndez-Rodr\u00edguez CM, Giannelli G, Sancho P, Fabregat I (2015) A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells. Int J Cancer 136(4):11","journal-title":"Int J Cancer"},{"issue":"7","key":"2601_CR33","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/ijc.29137","volume":"136","author":"S Mikami","year":"2015","unstructured":"Mikami S, Mizuno R, Kosaka T, Saya H, Oya M, Okada Y (2015) Expression of TNF-\u03b1 and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas. Int J Cancer 136(7):1504\u20131514","journal-title":"Int J Cancer"},{"key":"2601_CR34","unstructured":"Xie G, Yao Q, Liu Y, Du S, Liu A, Guo Z, Sun A, Ruan J, Chen L, Ye C, Yuan Y (2012)\u00a0IL-6-induced epithelial-mesenchymal transition promotes the generation of breast cancer stem-like cells analogous to mammosphere cultures. Int J Oncol 40(4):1171\u20131179"},{"key":"2601_CR35","doi-asserted-by":"crossref","unstructured":"Bellerby R, Smith C, Kyme S, Gee J, G\u00fcnthert U, Green A, Rakha E, Barrett-Lee P, Hiscox S (2016) Overexpression of specific CD44 isoforms is associated with aggressive cell features in acquired endocrine resistance. Front Oncol 6:145","DOI":"10.3389\/fonc.2016.00145"},{"issue":"9","key":"2601_CR36","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/jnci\/djn123","volume":"100","author":"X Li","year":"2008","unstructured":"Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. JNCI J Natl Cancer Inst 100(9):672\u2013679","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"2","key":"2601_CR37","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/bcr2559","volume":"12","author":"H Nakshatri","year":"2010","unstructured":"Nakshatri H (2010) Radiation resistance in breast cancer: are CD44+\/CD24-\/proteosomelow\/PKH26+cells to blame? Breast Cancer Res 12(2):105","journal-title":"Breast Cancer Res"},{"issue":"11","key":"2601_CR38","doi-asserted-by":"publisher","first-page":"9313","DOI":"10.18632\/oncotarget.3220","volume":"6","author":"Y Gao","year":"2015","unstructured":"Gao Y, Foster R, Yang X, Feng Y, Shen JK, Mankin HJ, Hornicek FJ, Amiji MM, Duan Z (2015) Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer. Oncotarget 6(11):9313\u20139326","journal-title":"Oncotarget"},{"issue":"45","key":"2601_CR39","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.18632\/oncotarget.27794","volume":"11","author":"C Nicolazzo","year":"2020","unstructured":"Nicolazzo C, Loreni F, Caponnetto S, Magri V, Vestri AR, Zamarchi R, Gradilone A, Facchinetti A, Rossi E, Cortesi E, Gazzaniga P (2020) Baseline CD44v6-positive circulating tumor cells to predict first-line treatment failure in patients with metastatic colorectal cancer. Oncotarget 11(45):4115\u20134122","journal-title":"Oncotarget"},{"issue":"2","key":"2601_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020753","volume":"22","author":"S Ghatak","year":"2021","unstructured":"Ghatak S, Hascall VC, Markwald RR, Misra S (2021) Folfox therapy induces feedback upregulation of CD44v6 through YB-1 to maintain stemness in colon initiating cells. Int J Mol Sci 22(2):753","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2601_CR41","doi-asserted-by":"publisher","first-page":"8811","DOI":"10.1007\/s13277-015-4755-6","volume":"37","author":"L Lv","year":"2016","unstructured":"Lv L, Liu H-G, Dong S-Y, Yang F, Wang Q-X, Guo G-L, Pan Y-F, Zhang X-H (2016) Upregulation of CD44v6 contributes to acquired chemoresistance via the modulation of autophagy in colon cancer SW480 cells. Tumor Biol 37(7):8811\u20138824","journal-title":"Tumor Biol"},{"issue":"5","key":"2601_CR42","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3892\/ol.2012.611","volume":"3","author":"K Mima","year":"2012","unstructured":"Mima K, Okabe H, Ishimoto T, Hayashi H, Nakagawa S, Kuroki H, Miyake K, Takamori H, Beppu T, Baba H (2012) The expression levels of CD44v6 are correlated with the invasiveness of hepatocellular carcinoma in vitro, but do not appear to be clinically significant. Oncol Lett 3(5):1047\u20131051","journal-title":"Oncol Lett"},{"issue":"4","key":"2601_CR43","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.3892\/or.2013.2273","volume":"29","author":"S Saito","year":"2013","unstructured":"Saito S, Okabe H, Watanabe M, Ishimoto T, Iwatsuki M, Baba Y, Tanaka Y, Kurashige J, Miyamoto Y, Baba H (2013) CD44v6 expression is related to mesenchymal phenotype and poor prognosis in patients with colorectal cancer. Oncol Rep 29(4):1570\u20131578","journal-title":"Oncol Rep"},{"issue":"1","key":"2601_CR44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00204-014-1424-2","volume":"89","author":"V Orian-Rousseau","year":"2015","unstructured":"Orian-Rousseau V, Ponta H (2015) Perspectives of CD44 targeting therapies. Arch Toxicol 89(1):3\u201314","journal-title":"Arch Toxicol"},{"key":"2601_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2007.10.009","author":"H Riechelmann","year":"2008","unstructured":"Riechelmann H, Sauter A, Golze W, Hanft G, Schroen C, Hoermann K, Erhardt T, Gronau S (2008) Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertan-sine in head and neck squamous cell carcinoma. Oral Oncol. https:\/\/doi.org\/10.1016\/j.oraloncology.2007.10.009","journal-title":"Oral Oncol"},{"issue":"10","key":"2601_CR46","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/nm1483","volume":"12","author":"L Jin","year":"2006","unstructured":"Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12(10):1167\u20131174","journal-title":"Nat Med"},{"issue":"1","key":"2601_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/1746-1596-9-79","volume":"9","author":"Z Li","year":"2014","unstructured":"Li Z, Chen K, Jiang P, Zhang X, Li X, Li Z (2014) CD44v\/CD44s expression patterns are associated with the survival of pancreatic carcinoma patients. Diagn Pathol 9(1):79","journal-title":"Diagn Pathol"},{"issue":"15","key":"2601_CR48","doi-asserted-by":"publisher","first-page":"6127","DOI":"10.1073\/pnas.1221841110","volume":"110","author":"S Zhang","year":"2013","unstructured":"Zhang S, Wu CCN, Fecteau J-F, Cui B, Chen L, Zhang L, Wu R, Rassenti L, Lao F, Weigand S, Kipps TJ (2013) Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proc Natl Acad Sci USA 110(15):6127\u20136132","journal-title":"Proc Natl Acad Sci USA"},{"key":"2601_CR49","doi-asserted-by":"crossref","unstructured":"Mortensen AC, Spiegelberg D, Haylock AK, Lundqvist H, Nestor M\u00a0(2018)\u00a0Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy. Int J Oncol 52(6):1875\u20131885","DOI":"10.3892\/ijo.2018.4364"},{"issue":"12","key":"2601_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e22594","volume":"9","author":"ACL Mortensen","year":"2023","unstructured":"Mortensen ACL, Imgenberg-Kreuz J, Spiegelberg D, Botling J, Nestor M (2023) Utilizing CD44v6 and V600EBRAF-mutation for in vitro targeted combination therapy of thyroid carcinomas. Heliyon 9(12):e22594","journal-title":"Heliyon"},{"key":"2601_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-35069-0","author":"S Patel","year":"2018","unstructured":"Patel S, Waghela B, Shah K, Vaidya F, Mirza S, Patel S, Pathak C, Rawal R (2018) Silibinin, a natural blend in polytherapy formulation for targeting Cd44v6 expressing colon cancer stem cells. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-018-35069-0","journal-title":"Sci Rep"},{"issue":"5","key":"2601_CR52","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1053\/j.gastro.2012.02.009","volume":"142","author":"SF Katz","year":"2012","unstructured":"Katz SF, Lechel A, Obenauf AC, Begus-Nahrmann Y, Kraus JM, Hoffmann EM, Duda J, Eshraghi P, Hartmann D, Liss B, Schirmacher P, Kestler HA, Speicher MR, Rudolph KL (2012) Disruption of Trp53 in livers of mice induces formation of carcinomas with bilineal differentiation. Gastroenterology 142(5):1229-1239.e3","journal-title":"Gastroenterology"},{"key":"2601_CR53","doi-asserted-by":"crossref","unstructured":"Chisari FV, C.A.P., Milich DR, Filippi P, McLachlan A, Palmiter RD and Brinster RL (1985)\u00a0A Transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Am\u00a0Assoc Adv Sci,\u00a0230(4730): 4.","DOI":"10.1126\/science.3865369"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-025-02601-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00109-025-02601-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-025-02601-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T06:38:32Z","timestamp":1764743912000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00109-025-02601-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":53,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2601"],"URL":"https:\/\/doi.org\/10.1007\/s00109-025-02601-5","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"7 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Before the start of the study, a positive ethics vote from the local ethics committee has been obtained (Ulm University, approval number: 72\/19).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Klaus Dembowsky is an employee of amcure GmbH. The other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}